DECLOPRAMIDE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H20ClN3O.ClH
Molecular Weight	306.231
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1

InChI

InChIKey=DMJHWHGTAHHHMU-UHFFFAOYSA-N

InChI=1S/C13H20ClN3O.ClH/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10;/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18);1H

HIDE SMILES / InChI

Molecular Formula	C13H20ClN3O
Molecular Weight	269.77
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9482687
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/10226556 |http://www.prnewswire.com/news-releases/oxigene-initiates-phase-ii-trials-for-declopramide-an-apoptosis-inducing-and-nf-kappa-beta-inhibiting-cancer-drug-candidate-76239792.html | http://adisinsight.springer.com/drugs/800007055

Declopramide is an apoptosis inducer. Also, it inhibits NFkappaB activation by inhibition of IkappaBbeta breakdown. In preclinical research, Declopramide demonstrated strong antitumor properties. It had been in phase II clinical trials for the treatment of colorectal cancer. However, this research has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3 (5-HT3) receptor 59 Target ID: CHEMBL2094116 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10194550	Binding Agent 1076
I-kappaB kinase/NF-kappaB signaling 4 Target ID: GO:0007249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10576654	Inhibitor 8504
Apoptosis 156 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10576654 \| http://www.prnewswire.com/news-releases/oxigene-initiates-phase-ii-trials-for-declopramide-an-apoptosis-inducing-and-nf-kappa-beta-inhibiting-cancer-drug-candidate-76239792.html	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Inflammatory bowel disease 24 Sources: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=15507 http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=25314	Primary	Preclinical	Unknown Approved Use Unknown
Colorectal cancer 102 Sources: http://www.prnewswire.com/news-releases/oxigene-initiates-phase-ii-trials-for-declopramide-an-apoptosis-inducing-and-nf-kappa-beta-inhibiting-cancer-drug-candidate-76239792.html	Primary	Phase II 1147	Unknown Approved Use Unknown
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9482687 https://www.ncbi.nlm.nih.gov/pubmed/10226556	Primary	Preclinical	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00H1P7	https://www.1pchem.com/search?query=1P00H1P7
A2B Chem	AH94555	http://a2bchem.com/prod/AH94555
Alfa Chemistry	ACM891601	http://www.alfa-chemistry.com/search.aspx?q=ACM891601
Chemspace	CSC001171102	https://chem-space.com/CSC001171102
eMolecules	276807381	https://orderbb.emolecules.com/search/#?query=276807381
Enamine	BBV-38940910	http://www.enaminestore.com/catalog/BBV-38940910
Enamine	EN300-1425545	https://www.enaminestore.com/catalog/EN300-1425545
MolPort	MolPort-004-952-397	https://www.molport.com/shop/molecule-link/MolPort-004-952-397
MuseChem	I006416	https://www.musechem.com/product/I006416.html
Selena	SEL12375801

PubMed

Title	Date	PubMed
Pharmacokinetics and splenic accumulation of N-acetylamino-3-chloro-N-(2-diethylamino-ethyl) benzamide after a single administration to rats.	2004-10	15386479
Mechanism of action for N-substituted benzamide-induced apoptosis.	2002-03-18	11953831

Patents

Sample Use Guides

In Vivo Use Guide

Rat: 50 mg/kg 3 times per day

Route of Administration: Other

In Vitro Use Guide

Human monocytic cells (THP-1) were exposed to 3-chloroprocainamide (3-CPA) at doses 0.2, 1 and 5 mM just before 5 h stimulation with LPS to induce cytokine production. In this experiment, dose dependent inhibition of TNFalpha was paralleled by an equivalent inhibition of IL-1B, IL-6 and IL-8.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:15:31 GMT 2025` Edited by `admin` on `Mon Mar 31 18:15:31 GMT 2025`
Record UNII	IP0ITJD3WD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DECLOPRAMIDE HYDROCHLORIDE

Common Name

English

BENZAMIDE, 4-AMINO-3-CHLORO-N-(2-(DIETHYLAMINO)ETHYL)-, MONOHYDROCHLORIDE

Preferred Name

English

BENZAMIDE, 4-AMINO-3-CHLORO-N-(2-(DIETHYLAMINO)ETHYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

3-CHLOROPROCAINAMIDE

Common Name

English

N-(DIETHYLAMINOETHYL)-4-AMINO-3-CHLOROBENZAMIDE HYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

CAS

52423-57-1

Created by admin on Mon Mar 31 18:15:31 GMT 2025 , Edited by admin on Mon Mar 31 18:15:31 GMT 2025

PRIMARY

FDA UNII

IP0ITJD3WD

Created by admin on Mon Mar 31 18:15:31 GMT 2025 , Edited by admin on Mon Mar 31 18:15:31 GMT 2025

PRIMARY

PUBCHEM

22737404

Created by admin on Mon Mar 31 18:15:31 GMT 2025 , Edited by admin on Mon Mar 31 18:15:31 GMT 2025

PRIMARY

Related Record Type Details


					916GJF577D

DECLOPRAMIDE

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Overview

OverviewOther

Sourcing

PubMed

Patents

Sample Use Guides